Patient Assistance Program
Introduction
Being diagnosed with a blood cancer or managing chronic graft-versus-host disease (cGVHD) often means navigating long-term treatment while balancing quality of life and treatment costs. Advances in targeted cancer therapies have provided new treatment options that focus on specific proteins involved in disease progression rather than relying solely on traditional chemotherapy.
Imbruvica is a prescription oral targeted therapy approved to treat several B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), and chronic graft-versus-host disease after other systemic treatments have failed. By blocking Bruton’s tyrosine kinase (BTK), Imbruvica helps interfere with signals that allow abnormal B cells to survive and multiply.
As a specialty oncology medication, Imbruvica can be expensive without adequate insurance coverage or financial assistance. Many patients searching for the Imbruvica patient assistance program are looking for ways to reduce out-of-pocket medication costs while maintaining access to treatment.
Prescription Hope offers access to patient assistance programs for qualified patients.
What Is the Imbruvica Patient Assistance Program?
Understanding Imbruvica Prescription Assistance
Due to the high cost of specialty medications, patients often search for affordable Imbruvica or Imbruvica savings programs.
Manufacturers understand that patients searching for medication like these need financial relief for their medication costs. Therefore, many manufacturers offer patient assistance programs to help qualified patients.
These programs provide affordable medications to qualified patients. However, many of them are difficult to navigate, leaving patients frustrated when applying on their own.
How Expert Advocates Help Make Imbruvica More Affordable
Personalized Medication Assistance
Patients looking for trusted prescription assistance specialists need look no further than Prescription Hope. Our patient support services take care of the application process for patient assistance programs, from start to finish.
We manage form completion, document and signature collection, coordination with healthcare providers and manufacturers, and all the bureaucracy that comes with patient assistance programs.
Ongoing Patient Support
Prescription Hope doesn’t just provide application assistance services, but also offers long-term medication assistance. Our team manages administrative tasks such as form and document updates, issue resolution, program monitoring, yearly renewals, and even refill scheduling.
Imbruvica Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Navigating Blood Cancer Treatment Costs
While oncology medications can be extremely expensive, Imbruvica cost assistance through Prescription Hope can make all the difference.
For $70.00 per month, per medication, patients get access to specialty oncology medication assistance without any hidden charges or fees, variable pricing systems, or medication costs.
And if we can’t help you save, you pay nothing!
Imbruvica Patient Assistance Eligibility
General Eligibility Requirements
While determining specific Imbruvica patient assistance qualifications is best done by enrolling with Prescription Hope, it’s good to understand general prescription assistance requirements. They include:
Income: Each program maintains its own income threshold.
Insurance: Each program maintains its own requirement regarding insurance coverage status.
Prescription: All qualified patients must have a valid prescription for their brand-name medication they wish to apply for.
U.S. Residency: All qualified patients must have legal U.S. residency.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Those who wish to enroll in Imbruvica assistance can enroll with Prescription Hope today. It only takes 6 steps:
- Submit Information: Our online form can be completed in a few minutes.
- Advocate Contact: A patient advocate will contact you within 1-2 business days.
- Document Collection: Following a quick prequalification, our team will collect needed documents
- Provider Coordination: We connect with your healthcare provider to secure vital signatures.
- Program Submission: Our team completes your application packet, submits it, and continues to follow up with the manufacturer.
- Medication Delivery: Once approved, qualified patients can typically expect to receive their medication within 2 weeks, though shipping times may vary. All medication shipments come directly from the manufacturer to your home or doctor’s office.
Understanding Imbruvica
How Imbruvica Works
Imbruvica is a Bruton’s tyrosine kinase (BTK) inhibitor that targets a key protein involved in the growth, survival, and signaling of certain B cells. In several blood cancers, abnormal B cells depend on BTK signaling to continue multiplying and avoiding normal cell death.
By blocking BTK, Imbruvica disrupts these signaling pathways, helping slow the growth of cancerous B cells and reduce the number of abnormal blood cells or lymphoma cells. In patients with chronic graft-versus-host disease (cGVHD), BTK inhibition also helps reduce abnormal immune system activity that contributes to ongoing tissue damage.
As a targeted oral therapy, Imbruvica offers an alternative to traditional chemotherapy for several approved blood cancers and immune-related conditions.
What Conditions Does Imbruvica Treat?
Imbruvica is FDA-approved to treat several B-cell malignancies and chronic graft-versus-host disease (cGVHD).
Approved indications include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL with 17p deletion, Waldenström’s macroglobulinemia (WM), and chronic graft-versus-host disease after failure of one or more lines of systemic therapy in adults and children 1 year of age and older.
Some previous FDA indications, including mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), were voluntarily withdrawn after confirmatory clinical trials did not verify clinical benefit.
Benefits of Treatment
Imbruvica provides a targeted treatment option for several blood cancers and chronic graft-versus-host disease by blocking BTK, a protein involved in abnormal B-cell signaling and immune activity.
Potential benefits include slowing disease progression, reducing enlarged lymph nodes, improving hematologic outcomes in appropriate patients, helping control symptoms of Waldenström’s macroglobulinemia, improving symptoms of chronic graft-versus-host disease after previous therapies have failed, and providing the convenience of a once-daily oral treatment option.
Treatment outcomes vary depending on the condition being treated and individual patient characteristics. Healthcare providers routinely monitor treatment response, blood counts, and overall disease status throughout therapy.
Important Safety Information and Side Effects
Imbruvica does not carry an FDA Boxed Warning.
The most commonly reported side effects include diarrhea, fatigue, muscle and joint pain, bruising, rash, nausea, fever, upper respiratory tract infections, low platelet counts, anemia, and neutropenia. Patients should contact their healthcare provider if side effects become severe, persistent, or concerning.
Imbruvica may cause serious and sometimes fatal bleeding (hemorrhage). Serious bleeding events have occurred with and without the use of blood-thinning medications. Patients should immediately report unusual bruising, blood in the urine or stool, vomiting blood, or severe or persistent bleeding. Healthcare providers may temporarily stop treatment before and after certain surgical procedures to reduce bleeding risk.
Treatment may increase the risk of serious bacterial, viral, and fungal infections. Patients should promptly report fever, chills, persistent cough, shortness of breath, or other signs of infection.
Serious cardiac problems have occurred during treatment, including atrial fibrillation, atrial flutter, ventricular arrhythmias, heart failure, and sudden cardiac death. Patients should seek immediate medical attention if they experience chest pain, rapid or irregular heartbeat, shortness of breath, dizziness, or fainting. Individuals with existing heart disease or cardiovascular risk factors may require closer monitoring.
Imbruvica may cause new or worsening high blood pressure (hypertension). Blood pressure should be monitored regularly throughout treatment.
Treatment may also lower white blood cells, red blood cells, and platelets (cytopenias). Routine complete blood counts are recommended to monitor for these changes during therapy.
Second primary cancers, including non-melanoma skin cancers and other malignancies, have been reported in patients receiving Imbruvica. Routine skin examinations and appropriate sun protection are recommended.
Imbruvica may cause fetal harm if used during pregnancy. Females of reproductive potential should use effective contraception during treatment and for the recommended period after the last dose. Male patients with female partners of reproductive potential should also follow contraceptive recommendations. Breastfeeding is not recommended during treatment and for one week after the final dose.
Imbruvica interacts with strong and moderate CYP3A inhibitors, strong CYP3A inducers, grapefruit, Seville oranges, and St. John’s wort, which may affect ibrutinib blood levels. Patients should inform their healthcare provider about all prescription medications, over-the-counter medicines, vitamins, and herbal supplements before beginning treatment.
Imbruvica is taken orally once daily and is available as capsules, tablets, and an oral suspension. It may be taken with or without food at approximately the same time each day. Capsules and tablets should be swallowed whole and should not be crushed, chewed, or broken. Treatment generally continues until disease progression or unacceptable toxicity occurs, and patients should not stop taking Imbruvica without consulting their healthcare provider.
Healthcare providers typically monitor complete blood counts, blood pressure, cardiac rhythm and function, signs of bleeding, signs of infection, treatment response, and skin health throughout therapy.
Access to Multiple Medications
Support Beyond Imbruvica
Looking for oncology medication support as well as other specialty medication access?
Prescription Hope routinely helps qualified patients access multiple medication assistance programs at once. Whether one or many, our team provides all services for a simple $70.00 per month, per medication.
Why Choose Prescription Hope for Imbruvica Assistance
Patient-Focused Medication Support
For two decades, patients with Prescription Hope have received patient-centered assistance and support that provides them with prescription affordability support. Our Florida-based medication access specialists can provide Imbruvica assistance through Prescription Hope.
Simplified Access to Specialty Medications
Our blood cancer medication access and prescription assistance help provide patients with the support they need to lower their medication costs and have peace of mind when it comes to prescription medication prices.
Ongoing Prescription Assistance
Not only does Prescription Hope help with blood cancer treatment support, but we also provide long-term medication support. Our team of patient advocates takes care of form and document updates, issue resolution, yearly renewals, program monitoring, and even refill scheduling.
If you need access to affordable brand-name medications like Imbruvica, then enroll with Prescription Hope today!